These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 35216850)
1. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia. Feller CN; Adams JA; Friedland DR; Poetker DM Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850 [TBL] [Abstract][Full Text] [Related]
2. Endoscopic-guided coblation treatment of nasal telangiectasias in hereditary hemorrhagic telangiectasia: "How I do it". Poetker DM Am J Rhinol Allergy; 2017 May; 31(3):205-206. PubMed ID: 28490409 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review. Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788 [TBL] [Abstract][Full Text] [Related]
4. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]. Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517 [TBL] [Abstract][Full Text] [Related]
6. Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review. Thiele B; Abdel-Aty Y; Marks L; Lal D; Marino M Ann Otol Rhinol Laryngol; 2023 Jan; 132(1):82-90. PubMed ID: 35152768 [TBL] [Abstract][Full Text] [Related]
7. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization. Khanwalkar AR; Rathor A; Read AK; Paknezhad H; Ma Y; Hwang PH Int Forum Allergy Rhinol; 2022 Aug; 12(8):1034-1042. PubMed ID: 34989143 [TBL] [Abstract][Full Text] [Related]
8. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia. Khoueir N; Borsik M; Camous D; Herman P; Verillaud B Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760 [TBL] [Abstract][Full Text] [Related]
9. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia]. Xu C; Wang HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893 [TBL] [Abstract][Full Text] [Related]
10. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia]. Zhang J; Wang XS; Wang HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995 [No Abstract] [Full Text] [Related]
11. Postoperative Pain Following Coblation of Sinonasal Hereditary Hemorrhagic Telangiectasias. Kraimer K; Scott B; Farrell N; Geltzeiler M; Smith T; Detwiller K Ann Otol Rhinol Laryngol; 2024 Jan; 133(1):58-62. PubMed ID: 37377016 [TBL] [Abstract][Full Text] [Related]
12. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. Stokes P; Rimmer J Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422 [TBL] [Abstract][Full Text] [Related]
13. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Parambil JG; Woodard TD; Koc ON Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965 [TBL] [Abstract][Full Text] [Related]
14. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646 [TBL] [Abstract][Full Text] [Related]
15. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients. Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613 [TBL] [Abstract][Full Text] [Related]
16. Intranasal bevacizumab injections improve quality of life in HHT patients. Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573 [TBL] [Abstract][Full Text] [Related]
17. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329 [TBL] [Abstract][Full Text] [Related]